Pharmacokinetics and Tolerability of Sulthiame

PHASE1CompletedINTERVENTIONAL
Enrollment

4

Participants

Timeline

Start Date

February 12, 2018

Primary Completion Date

May 22, 2018

Study Completion Date

August 30, 2018

Conditions
Epilepsy
Interventions
DRUG

Sulthiame

Single dose (50, 100, 200 mg)

Trial Locations (1)

1011

Division of Clinical Pharmacology, Lausanne

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Advicenne Pharma

INDUSTRY

lead

Centre Hospitalier Universitaire Vaudois

OTHER